Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YZJ-1139 in primary chronic insomnia (Phase II)
CTR20190656Phase 2Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fazamorexant in chronic insomnia, sponsored by Yangtze River Pharmaceutical Group. Started Apr 2019; status: completed.
02
Drugs
fazamorexant
03
Conditions
chronic insomnia
Beyond the preview
Go deeper on CTR20190656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190656.